Mesoblast Ltd. Daily Stock Analysis

Daily Stock Analysis, MESO, Mesoblast Ltd, priceseries

Mesoblast Ltd. Daily Stock Analysis
Stock Information
Open
3.68
Close
3.58
High
3.68
Low
3.55
Previous Close
3.77
Daily Price Gain
-0.19
YTD High
5.09
YTD High Date
Jan 4, 2022
YTD Low
3.55
YTD Low Date
Mar 7, 2022
YTD Price Change
-1.40
YTD Gain
-28.11%
52 Week High
9.87
52 Week High Date
Mar 16, 2021
52 Week Low
3.55
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-5.14
52 Week Gain
-58.94%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 5. 2017
5.49
Jan 20. 2017
5.83
10 Trading Days
6.29%
Link
LONG
Feb 10. 2017
5.83
Feb 27. 2017
6.13
10 Trading Days
5.07%
Link
LONG
Mar 16. 2017
7.95
Mar 31. 2017
8.57
11 Trading Days
7.79%
Link
LONG
Dec 6. 2017
5.14
Jan 3. 2018
5.80
18 Trading Days
12.75%
Link
LONG
Feb 20. 2018
5.27
Mar 8. 2018
7.11
12 Trading Days
34.92%
Link
LONG
Jul 16. 2018
6.00
Jul 25. 2018
6.41
7 Trading Days
6.91%
Link
LONG
Sep 17. 2018
6.11
Oct 2. 2018
7.42
11 Trading Days
21.40%
Link
LONG
Dec 28. 2018
3.95
Jan 22. 2019
4.70
15 Trading Days
18.88%
Link
LONG
Sep 10. 2019
6.08
Sep 24. 2019
6.72
10 Trading Days
10.60%
Link
LONG
Dec 4. 2019
6.27
Dec 18. 2019
6.76
10 Trading Days
7.82%
Link
LONG
Dec 23. 2019
7.03
Jan 31. 2020
9.70
26 Trading Days
37.91%
Link
LONG
May 4. 2020
10.71
Jun 5. 2020
12.86
21 Trading Days
20.06%
Link
LONG
Jun 8. 2021
7.61
Jun 25. 2021
8.16
13 Trading Days
7.17%
Link
Company Information
Stock Symbol
MESO
Exchange
NasdaqGS
Company URL
http://www.mesoblast.com
Company Phone
-
CEO
Silviu Itescu
Headquarters
-
Business Address
-
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
-
About

Mesoblast Ltd. engages in the research, development, and market of pharmaceutical products. Its medicines target the cardiovascular conditions, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Itescu Silviu on June 8, 2004 and is headquartered in Melbourne, Australia.

Description

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on specialized cells, known as mesenchymal lineage adult stem cells, to establish a portfolio of late-stage product candidates. Its allogeneic off-the-shelf cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory conditions, orthopedic disorders, and oncologic/hematologic conditions. The company's lead product candidates include MPC-150-IM, a Phase 3 product candidate under investigation for the treatment of chronic congestive heart failure; MPC-06-ID, a Phase 3 product candidate under investigation for the treatment of chronic low back pain due to disc degeneration; MSC-100-IV, a Phase 3 intravenously-delivered product candidate, which is developed for the treatment of acute graft versus host disease following allogeneic bone marrow transplantation; and MPC-300-IV, an intravenously-delivered immunomodulatory product candidate for the treatment of chronic inflammatory conditions, including biologic-refractory rheumatoid arthritis, and diabetic nephropathy, which is under Phase 2 trial. It has a collaboration agreement with JCR Pharmaceuticals Co., Ltd to offer TEMCELL HS. Inj., a product based on its proprietary mesenchymal lineage adult stem cell technology for the treatment of graft versus host disease. The company has operations in Australia, the United States, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited was founded in 2004 and is based in Melbourne, Australia.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading